People at risk for AD showed higher PM20D1 promoter methylation and reduced expression, while SNP carriers with reduced risk for AD displayed higher levels of PM20D1, which bestowed neuroprotection (Sanchez-Mut et al., 2018). This evidence concerns the gene PM20D1 and Alzheimer disease.